Figure 3: In vivo dosing of different forms of IL-2 in A/J Mice.
From: Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
(a) Animal mortality and morbidity, as assessed by survival (top) and weight loss (bottom); (b) accumulation of ascites and pleural fluid (representative syringe; top; average from all mice in the group; bottom) and (c) tissue inflammation after administration of wtIL-2 (arrows point to inflammatory infiltrates). All H+E figures presented at 200 × exposure with scale bar at bottom left=100 μm. (d) Animal mortality (top) and morbidity as assessed by weight loss (bottom) after administration of high dose wtIL-2 (left), OMCP-mutIL-2 (middle) and mutIL-2 (right) in anti-AsialoGM1 (solid line) or rabbit IgG-treated (dotted line) A/J mice. Weight loss compared by unpaired t-test at each individual day between NK sufficient and depleted mice. Kaplan–Meier survival graphs compared by Log-rank (Mantel–Cox) test. (e) Weight loss, (f) ascites (representative syringe-top; average from all mice in the group-bottom) and (g) organ inflammation in mice treated with 200,000 IUe of either wtIL-2, OMCP-mutIL-2 or mutIL-2. Comparison of ascites done by unpaired t-test between wt IL-2 and mutIL-2 and OMCP-mutIL-2 treated mice respectively. All H+E figures presented at 200 × exposure with scale bar at bottom left=100 μm. All graphs represent 4–6 A/J mice per treatment condition performed in at least two separate experiments. ns P>0.05; *P<0.05; black=saline; blue=wtIL-2, red=OMCP-mutIL-2, green=mutIL-2.
